Spotlight Speaker Presentation: Dr. Ekokobe Fonkem, DO — Neurologist–Neuro-Oncologist This summary captures the substance and spirit of Dr. Ekokobe Fonkem’s Spotlight Speaker presentation, delivered during MBTN’s 90-minute global webinar. It is written for the full community that the webinar was designed to serve — physicians and clinicians, meningioma survivor-thrivers and their families, caregivers, healthcare partners, community advocates, and grant funders alike — so that

Join the Meningioma Brain Tumor Network (MBTN) on Saturday, June 20th, for a powerful 90-minute global webinar: The Meningioma Enigma: Science, Lived Experience & Quality of Life! 🧠🌐 We are bringing together top medical experts and incredible survivor-thrivers for an interactive event dedicated to bridging the gap between clinical research and daily reality. During the event, we’ll be exploring: ✨ Navigating health-related quality of life outcomes. ✨ Addressing ps

The Meningioma Brain Tumor Network (MBTN) is proud to announce its upcoming global webinar, The Meningioma Enigma: Science, Lived Experience & Health‑Related Quality of Life, scheduled for June 20, 2026. This landmark event brings together leading experts in neuro‑oncology, clinical research, and survivor‑thriver advocacy to illuminate the complex realities of meningioma — the most prevalent primary brain tumor worldwide. Despite its frequency, meningioma remains widely misun

MBTN’s Survivor-Thriver Speaks program is a crucial platform that brings attention to often-neglected psychosocial symptoms experienced by patients throughout diagnosis and treatment. These symptoms—ranging from emotional distress and social isolation to anxiety and depression—can profoundly affect an individual’s overall health-related quality of life (HRQoL). By acknowledging and addressing these critical issues during diagnosis, our program aims to mitigate the long-term c

Carrie Borofka-Hilz Carrie Borofka‑Hilz is a meningioma survivor-thriver and patient advocate whose leadership is grounded in the lived experience of the neurological, sensory, and long‑term impacts of tumor treatment and survivor-thriver-ship. Diagnosed in 2012 with a Grade 2 Olfactory Groove Meningioma, she underwent surgical resection that resulted in complete blindness, later received radiation for tumor regrowth, and developed post‑surgical epilepsy due to the brain inju